Articles from AustinPx

AustinPx, a contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement for orally delivered small molecule drugs, today announced the introduction of the KinetiLease™ program, allowing pharmaceutical companies to lease the company’s KinetiSol™ research-scale equipment. This program enables companies to integrate this powerful amorphous dispersion manufacturing tool into their own R&D labs. Additionally, the company has announced the first equipment lease with a top 10 global biotech company.

AustinPx, developers of the next-generation amorphous dispersion platform, KinetiSol™ Technology, and a contract development and manufacturing organization (CDMO), is proud to announce that it has been named the winner of the Accelerating Innovation Award at the 2024 CPHI Pharma Awards for its groundbreaking KinetiSol Technology. The award recognizes outstanding achievement in solutions that address critical challenges within the pharmaceutical industry.

AustinPx, a leading contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement of orally delivered small molecule drug candidates, today announced its acquisition of a 3P Innovations API in capsule filling machine, a FT4 Powder Rheometer®, and the STYL’One Nano compaction simulator. The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.

AustinPx, developers of the next generation amorphous dispersion platform, KinetiSol™ Technology, and a contract development and manufacturing organization (CDMO), today announced that Elizabeth Hickman, chief business officer, will succeed Tim Scott in January 2025 as president and CEO of AustinPx. Scott has led the company’s new direction as a CDMO since 2022, successfully positioning the company’s leadership as an oral drug delivery dosage form development CDMO. Scott will stay on as executive chair following the transition and Hickman will be named to the Board of Directors.

AustinPx, a contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement of orally delivered small molecule drug candidates, and Microsize, a leading active pharmaceutical ingredient enhancement CDMO, today announced the strategic partnership to accelerate the commercial application of AustinPx’s KinetiSol® Technology platform. The collaboration will enable AustinPx’s clients to manufacture their late-phase clinical and commercial KinetiSol drug product intermediate at Microsize’s purpose built, FDA-inspected facility.

AustinPx, a contract development and manufacturing organization (CDMO) specializing in analytical and formulation development services and cGMP manufacturing for small molecule drugs, today announced the expansion of its capabilities to meet industry demand for the Company’s services and expertise. The Company has added new spray drying and encapsulation capabilities and has also expanded its GMP manufacturing capacity for high shear and fluid bed granulation.

AustinPx, Pharmaceutics and Manufacturing, a contract development and manufacturing organization (CDMO), today announced the appointment of Derek Hennecke and Marshall Crew as independent members of its board of directors. Appointments provide additional experienced CDMO leadership to drive growth in the complex formulation and manufacturing market

AustinPx, Pharmaceutics and Manufacturing, a contract development and manufacturing organization (CDMO), today announced the appointment of Elizabeth Hickman as Chief Business Officer (CBO). In this role, Ms. Hickman will be responsible for the Company’s CDMO business operations and strategy, including building capabilities and a team to deliver high-value solutions for pharmaceutical customers.